Notice of Intent to Sole Source Serology DV-1-4 EDIII Reagents

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price purchase order/contract to the University of North Carolina for custom-produced biotinylated EDIII antigens for Zika virus and dengue virus serotypes 1-4. These reagents are specifically designed for the CDC flavivirus serologic assay development and validation using streptavidin-based capture and multiplex immunoassay platforms. The requested HaloTag control antigen provides a matched control for assessing nonspecific binding, assay background, and reagent-related signal. • The CDC requires custom-produced biotinylated EDIII antigens for Zika virus and dengue virus serotypes 1-4. • The reagents are for the CDC flavivirus serologic assay development and validation. • The requested HaloTag control antigen provides a matched control for assessing nonspecific binding, assay background, and reagent-related signal. • Commercially available alternatives do not meet the Branch's technical requirements due to cross-reactive antibody binding, unsuitable tags, or potential variability in sequence, tag configuration, purity, lot consistency, or manufacturing method.